Bank of New York Mellon Corp lessened its position in Everest Group, Ltd. (NYSE:EG – Free Report) by 0.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 215,504 shares of the company’s stock after selling 1,767 shares during the period. Bank of New York Mellon Corp owned approximately 0.43% of Everest Group worth $70,438,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Geneos Wealth Management Inc. raised its holdings in shares of Everest Group by 98.9% during the first quarter. Geneos Wealth Management Inc. now owns 181 shares of the company’s stock valued at $66,000 after buying an additional 90 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in shares of Everest Group during the second quarter worth approximately $384,000. Marshall Wace LLP bought a new position in Everest Group in the 2nd quarter worth approximately $238,000. Jump Financial LLC bought a new position in Everest Group in the 2nd quarter worth approximately $1,510,000. Finally, Federated Hermes Inc. grew its holdings in Everest Group by 3.7% in the 2nd quarter. Federated Hermes Inc. now owns 14,411 shares of the company’s stock worth $4,898,000 after buying an additional 510 shares in the last quarter. 92.64% of the stock is currently owned by institutional investors.
Everest Group Stock Performance EG opened at $373.61 on Thursday. The company has a market capitalization of $14.78 billion, a price-to-earnings ratio of 7.60, a price-to-earnings-growth ratio of 0.59 and a beta of 0.29. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.37 and a quick ratio of 0.37. Everest Group, Ltd. has a 1-year low of $302.44 and a 1-year high of $385.68. The business has a 50 day moving average price of $351.44 and a two-hundred day moving average price of $339.68.
Everest Group (NYSE:EG – Get Free Report) last issued its quarterly earnings results on Monday, March 23rd. The company reported $16.08 earnings per share (EPS) for the quarter. Everest Group had a return on equity of 14.70% and a net margin of 11.76%.The firm had revenue of $4.07 billion during the quarter. Research analysts predict that Everest Group, Ltd. will post 52.86 EPS for the current fiscal year.
Everest Group Dividend Announcement The company also recently announced a quarterly dividend, which was paid on Friday, June 26th. Investors of record on Friday, June 12th were paid a dividend of $2.00 per share. The ex-dividend date of this dividend was Friday, June 12th. This represents a $8.00 annualized dividend and a yield of 2.1%. Everest Group’s dividend payout ratio (DPR) is currently 16.27%.
Key Everest Group News Here are the key news stories impacting Everest Group this week:
Positive Sentiment: Zacks noted Everest Group may be positioned to beat upcoming earnings estimates, which could support the stock if results come in ahead of expectations. Article Title Positive Sentiment: Analysts set a price target of $387.73, suggesting some Wall Street upside remains from current levels. Article Title Positive Sentiment: Everest Group’s own profile as a leader in insurance/reinsurance remains intact, and another company’s recognition in Everest Group’s healthcare CXM assessment highlights the firm’s industry relevance. Article Title Neutral Sentiment: One commentary piece argued against the stock, but it did not include any new company-specific operating news. Article Title Negative Sentiment: Zacks Research cut EPS estimates for several periods, including Q2 2026, FY2026, Q1/Q2/Q3/Q4 2027, FY2027, and FY2028, which can weigh on sentiment by implying slightly slower earnings momentum. Article Title Insider Transactions at Everest Group In related news, CEO Jason Keen sold 775 shares of Everest Group stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $351.84, for a total transaction of $272,676.00. Following the transaction, the chief executive officer directly owned 8,170 shares of the company’s stock, valued at $2,874,532.80. The trade was a 8.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.70% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades EG has been the topic of several recent analyst reports. Mizuho lifted their target price on Everest Group from $388.00 to $418.00 and gave the company a “neutral” rating in a research note on Thursday, July 9th. Wells Fargo & Company increased their price target on Everest Group from $356.00 to $373.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. UBS Group set a $355.00 price target on Everest Group in a report on Thursday, May 21st. Atlantic Securities set a $484.00 price objective on shares of Everest Group in a research note on Wednesday, July 15th. Finally, Barclays lifted their price objective on shares of Everest Group from $380.00 to $420.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. Four equities research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $387.73.
View Our Latest Stock Report on Everest Group
Everest Group Company Profile (Free Report)
Everest Group (NYSE:EG) is a global research and consulting firm specializing in strategic advisory, market intelligence, and data-driven analysis for business process, information technology, and emerging technology services. The company provides insights and benchmarks that help enterprises and service providers optimize digital transformation initiatives, sourcing strategies, and operational performance. Through its proprietary research frameworks and data analytics, Everest Group delivers actionable guidance on areas such as automation, cloud migration, customer experience, and supply chain resilience.
With offerings that span advisory engagements, managed services research, and consulting projects, Everest Group serves multiple industry verticals, including banking and financial services, healthcare, manufacturing, telecommunications, and retail.
See Also Five stocks we like better than Everest Group Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play Want to see what other hedge funds are holding EG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Everest Group, Ltd. (NYSE:EG – Free Report).
Receive News & Ratings for Everest Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Everest Group and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEWintrust Financial Corporation $WTFC Stock Holdings Increased by California Public Employees Retirement System
NEXT HEADLINE »Alamar Capital Management LLC Invests $2.35 Million in Fortinet, Inc. $FTNT
Wall Street expects a year-over-year decline in earnings on lower revenues when Everest Group (EG - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on July 29, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis reinsurance company is expected to post quarterly earnings of $14.59 per share in its upcoming report, which represents a year-over-year change of -16%.
Revenues are expected to be $4.09 billion, down 9% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.14% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Everest Group?For Everest Group, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +1.67%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that Everest Group will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Everest Group would post earnings of $14.03 per share when it actually produced earnings of $16.08, delivering a surprise of +14.61%.
Over the last four quarters, the company has beaten consensus EPS estimates two times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Everest Group appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry PlayerAmong the stocks in the Zacks Insurance - Multi line industry, Slide Insurance Holdings, Inc. (SLDE - Free Report) , is soon expected to post earnings of $0.88 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of +57.1%. This quarter's revenue is expected to be $370.8 million, up 41.7% from the year-ago quarter.
The consensus EPS estimate for Slide Insurance Holdings, Inc. has been revised 6.3% lower over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +7.43%.
When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Slide Insurance Holdings, Inc. will most likely beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
California Public Employees Retirement System cut its holdings in Everest Group, Ltd. (NYSE:EG – Free Report) by 11.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 94,010 shares of the company’s stock after selling 12,645 shares during the quarter. California Public Employees Retirement System owned 0.19% of Everest Group worth $30,727,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the business. Assetmark Inc. lifted its position in shares of Everest Group by 2.7% during the 1st quarter. Assetmark Inc. now owns 287,847 shares of the company’s stock valued at $94,083,000 after buying an additional 7,539 shares in the last quarter. Bessemer Group Inc. increased its holdings in Everest Group by 0.4% in the 1st quarter. Bessemer Group Inc. now owns 10,403 shares of the company’s stock worth $3,401,000 after acquiring an additional 42 shares in the last quarter. Wealthfront Advisers LLC raised its position in Everest Group by 17.9% during the first quarter. Wealthfront Advisers LLC now owns 835 shares of the company’s stock worth $273,000 after acquiring an additional 127 shares during the period. Twin Capital Management Inc. raised its position in Everest Group by 1.6% during the first quarter. Twin Capital Management Inc. now owns 3,978 shares of the company’s stock worth $1,300,000 after acquiring an additional 64 shares during the period. Finally, Illinois Municipal Retirement Fund lifted its holdings in Everest Group by 40.0% during the first quarter. Illinois Municipal Retirement Fund now owns 13,401 shares of the company’s stock valued at $4,380,000 after purchasing an additional 3,827 shares in the last quarter. 92.64% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets In other news, CEO Jason Keen sold 775 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $351.84, for a total transaction of $272,676.00. Following the transaction, the chief executive officer directly owned 8,170 shares in the company, valued at $2,874,532.80. The trade was a 8.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.70% of the stock is owned by company insiders.
Analysts Set New Price Targets Several brokerages have recently issued reports on EG. Weiss Ratings upgraded shares of Everest Group from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, July 10th. Atlantic Securities set a $484.00 price target on shares of Everest Group in a research note on Wednesday, July 15th. Evercore set a $375.00 price objective on Everest Group in a report on Friday, July 10th. Morgan Stanley boosted their price objective on Everest Group from $355.00 to $360.00 and gave the stock an “equal weight” rating in a research note on Monday, July 6th. Finally, Cantor Fitzgerald increased their target price on Everest Group from $344.00 to $390.00 and gave the company a “neutral” rating in a report on Thursday, July 9th. Four equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $387.73.
View Our Latest Stock Analysis on EG
Everest Group Price Performance Shares of NYSE EG opened at $376.88 on Wednesday. The firm has a 50-day simple moving average of $350.92 and a 200-day simple moving average of $339.45. The stock has a market capitalization of $14.91 billion, a price-to-earnings ratio of 7.66, a price-to-earnings-growth ratio of 0.59 and a beta of 0.29. The company has a quick ratio of 0.37, a current ratio of 0.37 and a debt-to-equity ratio of 0.23. Everest Group, Ltd. has a 52 week low of $302.44 and a 52 week high of $385.68.
Everest Group (NYSE:EG – Get Free Report) last posted its quarterly earnings results on Monday, March 23rd. The company reported $16.08 earnings per share for the quarter. Everest Group had a net margin of 11.76% and a return on equity of 14.70%. The firm had revenue of $4.07 billion for the quarter. On average, equities analysts predict that Everest Group, Ltd. will post 52.86 earnings per share for the current fiscal year.
Everest Group Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Friday, June 26th. Shareholders of record on Friday, June 12th were paid a $2.00 dividend. This represents a $8.00 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend was Friday, June 12th. Everest Group’s dividend payout ratio (DPR) is 16.27%.
Key Stories Impacting Everest Group Here are the key news stories impacting Everest Group this week:
Neutral Sentiment: Zacks Research slightly raised its Q3 2026 EPS estimate for Everest Group, which is a small positive offset amid broader estimate cuts. Everest Group, Ltd. (NYSE:EG) report Negative Sentiment: Analysts lowered Everest Group’s FY2026 earnings estimate, signaling a somewhat softer profit outlook for the current year. Everest Group, Ltd. (NYSE:EG) report Negative Sentiment: Additional downward revisions to FY2027 and FY2028 EPS estimates suggest analysts see less upside in long-term earnings growth than before. Everest Group, Ltd. (NYSE:EG) report Negative Sentiment: A separate commentary piece flagged “3 reasons to sell EG,” which may add to negative investor sentiment, even though it does not include new company-specific fundamentals. 3 reasons to sell EG and 1 stock to buy instead Everest Group Company Profile (Free Report)
Everest Group (NYSE:EG) is a global research and consulting firm specializing in strategic advisory, market intelligence, and data-driven analysis for business process, information technology, and emerging technology services. The company provides insights and benchmarks that help enterprises and service providers optimize digital transformation initiatives, sourcing strategies, and operational performance. Through its proprietary research frameworks and data analytics, Everest Group delivers actionable guidance on areas such as automation, cloud migration, customer experience, and supply chain resilience.
With offerings that span advisory engagements, managed services research, and consulting projects, Everest Group serves multiple industry verticals, including banking and financial services, healthcare, manufacturing, telecommunications, and retail.
Featured Articles Five stocks we like better than Everest Group Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding EG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Everest Group, Ltd. (NYSE:EG – Free Report).
Receive News & Ratings for Everest Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Everest Group and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECalifornia Public Employees Retirement System Has $29.66 Million Stock Holdings in The Estee Lauder Companies Inc. $EL
NEXT HEADLINE »California Public Employees Retirement System Sells 31,661 Shares of Bunge Global SA $BG
NEW YORK--(BUSINESS WIRE)--Global digital services leader TP (formerly Teleperformance) today announced it has been named a Leader in Everest Group's Healthcare CXM Intelligent Operations PEAK Matrix® Assessment, reinforcing its position as a strategic partner for healthcare organizations navigating rising complexity, regulatory demands, and growing consumer expectations. Everest Group evaluated 24 providers in this year's assessment, with TP ranked among the top performers for delivering high-.
Key Takeaways Reinsurance Treaty and Global Wholesale & Specialty driving underwriting growth and profitability. Higher investment income and global expansion support earnings and long-term growth opportunities.EG enhances shareholder returns through dividends, share buybacks and disciplined capital management. Shares of Everest Group, Ltd. (EG - Free Report) have risen 17.7% in the past year, outperforming the industry’s growth of 6.1%. The stock closed at $377.89 on Monday, near its 52-week high of $379.22, reflecting investor confidence.
EG shares have risen because of stronger-than-expected earnings, a much better combined ratio, lower catastrophe losses, solid investment income and confidence in management's specialty insurance and reinsurance strategy.
1-Year Price Performance: EG, AEG, AIZ, AIG & Industry
Image Source: Zacks Investment Research
Shares of other insurers like American International Group (AIG - Free Report) , Aegon NV (AEG - Free Report) and Assurant, Inc. (AIZ - Free Report) have gained 9.4%, 12.5% and 17.6% respectively in the past year.
EG’s Attractive ValuationEG’s shares are trading at a discount compared with the industry. Its price-to-book value of 0.98X is lower than the industry average of 2.98X. The insurer has a Value Score of A.
Image Source: Zacks Investment Research
Shares of other insurers like American International, Aegon and Assurant are trading at a discount to the industry average.
EG’s Growth ProjectionThe Zacks Consensus Estimate for Everest Group’s 2026 earnings per share (EPS) is pinned at $53.05, indicating a year-over-year increase of 19.1%. The estimate for 2026 revenues is pegged at $15.94 billion, implying a year-over-year decline of 8.9%. The consensus estimate for 2027 EPS indicates an increase of 13.2%, while revenues indicate a decrease of 3.7% from the corresponding 2026 estimates.
EG’s earnings grew 18% in the last five years, better than the industry average of 10.7 %. The expected long-term earnings growth is pegged at 12.4%.
Optimistic Analyst Sentiment on EGThe company has witnessed four upward earnings estimate revisions for 2026 over the past 60 days, against two downward revisions. For 2027, it has witnessed three upward revisions and one downward revision. Thus, the Zacks Consensus Estimate for 2026 and 2027 earnings has moved north by 0.6% and north 0.2%, respectively, over the same period.
EG’s Return on Invested CapitalThe return on invested capital in the trailing 12 months was 9.7%, better than the industry average of 2.2%. This reflects the company’s efficiency in utilizing funds to generate income.
What Drives EG?Reinsurance Treaty remains Everest Group's key growth engine, supported by disciplined underwriting, favorable reserve development and strong underwriting profitability. The Global Wholesale & Specialty business continues to gain traction, benefiting from portfolio optimization, improved underwriting and growth in higher-margin specialty lines. Although property catastrophe pricing has moderated, management remains disciplined, deploying capital only where risk-adjusted returns meet its profitability thresholds, supporting sustainable long-term earnings growth.
Everest Group continues to enhance portfolio quality by reducing exposure to lower-return casualty and retail insurance businesses while expanding higher-margin specialty and short-tail lines. The company also maintains conservative reserve practices, with favorable property reserve development and no material adverse U.S. casualty reserve movements, reflecting disciplined risk management and supporting earnings quality.
Net investment income has been improving, supported by strong alternative investment returns and growth in the fixed-income portfolio. Higher limited partnership income and expanding assets under management are expected to support investment returns.
Everest Group is actively scaling operations in markets such as Mexico, Colombia, Australia, and Italy, targeting regions with strong insurance demand and underpenetrated segments. Mexico and Colombia offer growth opportunities, driven by rising insurance adoption and demand for customized solutions. Australia and Italy provide exposure to developed markets with an increasing need for specialty and non-life coverage.
Everest Group is improving capital efficiency through the sale of its Commercial Retail Insurance business and the runoff of legacy operations, while the expanding Mt. Logan platform supports additional underwriting capacity and returns. The company also maintains a strong cash position and continues to enhance shareholder returns through regular dividends and an aggressive share repurchase program. Management expects a minimum quarterly buyback pace of $300 million throughout 2026.
Risks for EG StockProperty catastrophe reinsurance pricing continues to soften, which may weigh on premium growth and margins despite favorable policy terms.
Everest Group faces foreign exchange risk as it operates in currencies such as the euro, pound, and Canadian dollar while reporting in U.S. dollars.
Everest Group remains vulnerable to large catastrophe losses and geopolitical events. Large natural disasters or geopolitical events could increase claims and adversely impact underwriting profitability.
ConclusionEverest Group is poised for growth in underwriting discipline, international insurance expansion, a rise in investment income and financial flexibility. However, foreign exchange volatility, geopolitical tensions and catastrophe losses continue to be concerns.
Coupled with attractive valuation, optimistic analyst sentiment and higher returns, it is wise to retain this Zacks Rank #3 (Hold) stock presently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (NYSE: CTEV), a technology, data, and insights company focused on making healthcare more affordable and transparent, today announced it has been recognized as a Leader in the Everest Group Pre-payment Integrity Solutions PEAK Matrix® Assessment 2026. The recognition and ascent into the Leader category reflects Claritev's longstanding history and continued investment in technology-enabled payment integrity that helps health plans identify potent.
On July 02, 2026, Everest Group Ltd (EG) shares rose 3.2% to a current price of $371.35. This price reflects a strong upward trend, with the stock moving within
Everest Group delivered outstanding Q1-2026 results, with net income of $653M ($16.21/share) and a 16.8% ROE, underscoring robust earnings power. EG trades at a compelling valuation, generating $60–$65 annualized EPS while priced at $320–$360, with tangible book value near $407/share and a conservative $420/share target by Jan 2027. Despite competitive pressures and softening property catastrophe pricing, EG maintains structural discipline, focusing on profitability and selective capacity deployment.
HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. (“Everest”) (NYSE: EG) will hold its second quarter 2026 earnings conference call on Thursday, July 30, 2026, beginning at 8:00 am Eastern Time.
Dial in details can be obtained by completing the registration form available at: https://dpregister.com/sreg/10209412/10411df5d80
The call can be accessed via a live, listen only webcast at www.investors.everestglobal.com where a replay of the call will also be available.
Everest will release financial results on July 29, 2026 after the NYSE market close. At that time, Everest’s earnings release and financial supplement will be made available at www.investors.everestglobal.com.
About Everest
Everest is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers’ most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide.
Everest common stock (NYSE: EG) is a component of the S&P 500 index.
Additional information about Everest, our people, and our products can be found on our website at www.everestglobal.com.
Key Takeaways EG's net investment income delivered a 27% CAGR from 2020 to 2025, reflecting sustained portfolio growth. NII rose 15.5% year over year in first-quarter 2026, driven by fixed income and alternative investments. Growing insurance float, higher reinvestment yields, and disciplined portfolio management support earnings. Everest Group, Ltd. (EG - Free Report) has become one of the major beneficiaries of the higher interest rate environment, with net investment income (NII) serving as an increasingly important contributor to earnings alongside its insurance and reinsurance underwriting operations.
NII has become an increasingly valuable component of Everest Group's earnings profile. The combination of a growing insurance float, disciplined investment management, and a higher-yield investment environment strengthens the company's ability to generate consistent profits, complementing its underwriting performance and supporting long-term shareholder value creation.
A significant portion of the investment portfolio consists of fixed income securities, and smaller portions consist of equity securities and other investments, such as limited partnerships and other alternative investments. The metric should continue to gain from an increase in limited partnership income, higher income from fixed maturity investments, an increase in income from other alternative investments, higher income from short-term investments, and cash.
The insurer’s investment income has shown continuous improvement. The metric has delivered a five-year (2020-2025) CAGR of 27%.
NII increased 15.5% year over year for the three months ended March 31, 2026, largely driven by strong alternative asset returns, fixed income portfolio growth, and strong limited partnership returns.
EG's net investment income is primarily driven by the growth of its investment portfolio, higher reinvestment yields in a higher-rate environment, expanding insurance float, and disciplined portfolio management.
NII significantly boosts top-line growth and overall profitability for EG, complementing the company's underwriting operations. While insurance premiums are the primary source of revenue, NII provides a recurring stream of earnings generated from investing the company's insurance float and shareholders' capital.
What About Other Insurers?Chubb Limited's (CB - Free Report) net investment income is an important earnings contributor. The metric benefits from higher interest rates and stronger portfolio yields, providing a steady source of earnings beyond underwriting profits. This helps improve profitability, offset claim volatility and strengthen overall financial performance.
The Travelers Companies, Inc.’s (TRV - Free Report) net investment income is a material contributor to the company’s results of operations, consistently providing a reliable source of earnings that complements its underwriting activities. Net investment income acts as a second earnings engine for this property and casualty insurer after underwriting profit. Thus, even if underwriting profit weakens because of higher catastrophe losses, solid net investment income can help offset earnings pressure.
EG’s Price PerformanceShares of EG have gained 1.8% in the past year, outperforming the industry.
Image Source: Zacks Investment Research
EG’s UndervaluationThe stock is overvalued compared with its industry. It is currently trading at a price-to-book value multiple of 0.89, lower than the industry average of 2.78. It carries a Value Score of A.
Image Source: Zacks Investment Research
Estimate Movement for EGThe Zacks Consensus Estimate for EG’s second-quarter 2026 and third-quarter 2026 EPS has moved down 0.1% and 0.2%, respectively, in the past 30 days. The same for full-year 2026 EPS has moved up 0.9% in the past 30 days.
HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. (“Everest” or “the Company”) (NYSE: EG), a global specialty (re)insurance leader, today announced that it has partnered with Stone Point Insurance Solutions to launch Annapurna Re Ltd. (“Annapurna”), a Bermuda-based casualty reinsurance sidecar. Funds managed by Stone Point will serve as the inaugural, anchor investors in this multi-year vehicle.
As part of the transaction, Annapurna is expected to deploy approximately $600 million of third-party capital, providing dedicated reinsurance capacity to support Everest’s global casualty and specialty reinsurance portfolios over a three-year underwriting period.
“Annapurna sharpens our edge in casualty reinsurance and supports our long-term strategy through underwriting excellence and disciplined capital management,” said Jim Williamson, President and Chief Executive Officer of Everest. “Through our partnership with Stone Point, we are bringing additional high-quality capital to our platform in a scalable structure, enabling us to grow efficiently while enhancing our capital flexibility and positioning us to pursue the most attractive opportunities.”
"Annapurna Re represents the latest example of Stone Point's long history of investing in the insurance and reinsurance industry," said Jim Carey, Co-CEO of Stone Point. "Over many years, we have built a substantial asset management business serving the industry's capital needs. By combining the complementary capabilities of Everest and Stone Point, with support from strategic investor Mubadala, we believe Annapurna Re is well positioned to create value and deliver attractive outcomes for all stakeholders."
Annapurna builds on Everest’s established third-party capital capabilities, including its Mt. Logan platform. The vehicle combines Everest’s underwriting expertise with Stone Point’s experience in insurance-focused investment strategies. Stone Point Credit will serve as the exclusive investment manager.
This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Everest intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the U.S. federal securities laws. Forward-looking statements reflect management’s current expectations based on assumptions we believe are reasonable but are not guarantees of performance. Actual results may differ materially from those contained in forward-looking statements made on behalf of the Company.
About Everest
Everest Group, Ltd. (Everest) is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers’ most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide.
Everest common stock (NYSE: EG) is a component of the S&P 500 index.
Additional information about Everest, our people, and our products can be found on our website at www.everestglobal.com.
About Stone Point
Stone Point is a leading investment firm with more than $80 billion in assets under management across private equity, credit and insurance solutions. Drawing on more than three decades of experience and sector specialization, the firm focuses on the financial services industry and related sectors. Stone Point invests in and partners with talented management teams primarily based in North America and Western Europe. In addition, our capital markets team supports the firm, portfolio companies and other clients by providing custom financing solutions. Stone Point is headquartered in Greenwich, Connecticut, with offices in New York and Palm Beach. For more information, please visit www.stonepoint.com.
Magnit achieved Leader status in Everest Group’s global, North America, and EMEA assessments and Star Performer status in EMEA
FOLSOM, Calif.--(BUSINESS WIRE)--Magnit Global™, the global leader in contingent workforce management solutions, today announced its designation as a Leader in the 2026 Vendor Management System (VMS) PEAK Matrix® Assessment released by Everest Group. Magnit achieved Leader distinction in all regions measured: global, North America, and EMEA. In addition, Magnit was recognized as a Star Performer in EMEA for its year-over-year regional growth and positive client feedback.
Everest Group’s PEAK Matrix® assessment analyzes the VMS landscape and performance of nearly 50 service providers. It offers comparative evaluations of providers, locations, and products and solutions within various market segments. It provides unbiased evaluation of factors such as vision, capabilities/functionality, talent availability, market success/impact, and cost.
The report divides VMS providers into three main categories: Leaders, Major Contenders, and Aspirants.
“Magnit Global advanced its platform capabilities through AI-led innovation, deeper ecosystem integrations, and expanded multi-channel orchestration to manage contingent programs at scale,” says Krishna Charan, Vice President at Everest Group. “Its investments in Maggi, spanning candidate, workflow, knowledge, and reporting agents, along with enhanced services procurement functionality, SourceMatch, and Pay Intelligence, reinforce its position as a Leader in Everest Group’s 2026 Global Vendor Management System (VMS) PEAK Matrix® Assessment.”
Magnit earned Leader distinction for its ability to provide end-to-end contingent workforce management through a robust global footprint that serves diverse industries. The assessment highlighted several of Magnit’s strengths including:
Embedded Generative AI: Key functionalities provided by Maggi, Magnit’s GenAI agent, improve decision-making, automate workflows, and deliver predictive workforce insights. SOW and Services Procurement: AI-assisted SOW creation and enhanced collaboration and flexibility ease the SOW process. Direct Sourcing: Supporting client-specific talent pools and Magnit’s talent redeployment marketplace enable better access to talent. Data and Analytics: Magnit VMS users gain better insights from real-time dashboards, predictive analytics, and supplier scorecards. “Magnit Global is proud to be recognized as a global and regional Leader for our Vendor Management System. This acknowledgement reflects our investment in providing AI-enabled, data-driven solutions that help our clients unlock smarter, faster, more cost-effective ways to manage their contingent workforce and drive business growth.”
– Chandra Dhandapani, Magnit Global CEO
Read more about Everest Group’s 2026 PEAK Matrix® Assessment of Magnit VMS here.
About Magnit Global
Magnit is a leading provider of contingent workforce management solutions, helping enterprises source, manage, and optimize their extended workforces at scale. Through its proprietary VMS, managed services, and supplier intelligence platforms, Magnit delivers the visibility, compliance, and cost control that modern workforce programs demand. For more information, visit magnitglobal.com.
About Everest Group’s PEAK Matrix® Reports
Licensed extracts taken from Everest Group’s PEAK Matrix® Reports may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.
DETROIT--(BUSINESS WIRE)--Altimetrik, an AI-first data and digital engineering company, has been recognized as a “Major Contender” in the Everest Group Software Product Engineering Services PEAK Matrix® Assessment 2026.
The assessment evaluated 52 engineering service providers across the global software product engineering market, which Everest Group estimates at roughly $40 billion and projects to grow 6 to 7 percent this year. Providers were scored on market impact as well as vision and capability. Altimetrik’s revenue growth placed it among the faster-growing providers in the assessment.
“The firm has built a strong presence through offerings across multiple industries, a diversified client portfolio, and a partner-led ecosystem emphasizing collaboration with emerging data and AI partners such as OpenAI, Snowflake, and Databricks,” said Manukrishnan SR, Practice Director at Everest Group. “Its acquisition of SLK Software has helped it gain a foothold in the BFSI and manufacturing verticals, while dedicated CoE-led initiatives around holistic AI have further augmented its capabilities. An evolving IP portfolio centered on improving developer productivity reinforces its engineering strength.”
Everest Group highlighted Altimetrik’s ability to serve a balanced client base across technology-led segments such as ISVs and internet companies, as well as service-oriented industries including financial services, health care, and retail, with strong coverage across small, mid-sized, and large enterprises. The firm also earned recognition for its outcome-based and hybrid pricing models, which tie commercial terms to measurable client results rather than headcount or effort.
“Being recognized by Everest Group as a Major Contender in software product engineering validates what we’ve believed from day one: that engineering discipline is the foundation every great product is built on,” said Raj Sundaresan, CEO of Altimetrik. “As AI reshapes how software is designed and delivered, Altimetrik is ensuring that rigor scales with it. ALTi AIOS, our AI engineering operating system that embeds accountability and governance across the lifecycle, our partnership with OpenAI, and our recent inclusion in Google Cloud’s AI-native partner cohort are proof that we’re not just keeping pace, we’re setting the standard.”
Learn more about Altimetrik’s software product engineering capabilities.
About Altimetrik
Altimetrik is an AI engineering company, building the systems that power the modern enterprise. Through ALTi AIOS™, its AI engineering operating system, and a partner ecosystem that includes OpenAI, Google Cloud, Anthropic, Snowflake, and Databricks, Altimetrik enables organizations to build, govern, and scale enterprise-grade AI solutions to build sustainable competitive advantage.
With more than 10,000 practitioners worldwide and deep engineering DNA, Altimetrik helps businesses across BFSI, manufacturing, retail and CPG, automotive, health care, and life sciences.
Recognized in the 2025 Constellation Research ShortList™ for Global AI Services and named a Major Contender in multiple Everest Group PEAK Matrix® assessments, including Software Product Engineering Services (2026), Enterprise Quality Engineering Services (2025), and Digital Engineering Services for BFSI and Life Sciences. Learn more at altimetrik.com.
Key Takeaways EG Q1 EPS of $16.08 beat estimates, surging 149% YoY on strong reinsurance performance.Everest Group investment income rose 15.5%, while underwriting swung to $316M profit.EG revenues fell 4.6% on lower premiums, though the combined ratio improved to 91.2. Everest Group, Ltd. (EG - Free Report) reported first-quarter 2026 operating income of $16.08 per share, which beat the Zacks Consensus Estimate by 14.6%. The bottom line increased significantly 149% year over year.
Everest Group benefited from solid investment income growth and improved catastrophe losses, which driving a sharp improvement in profitability despite weaker premiums and top-line pressure.
EG’s Q1 Operational UpdateTotal operating revenues of about $4 billion declined 4.6% year over year, reflecting lower premiums. The top line missed the Zacks Consensus Estimate by 7.7%.
Gross written premiums fell 18.5% year over year to $3.6 billion, reflecting an 8.5% decline in Reinsurance Treaty, partially offset by growth in Global Wholesale &Specialty. Our estimate was $4.8 billion.
Net investment income rose 15.5% year over year to $567 million, driven by a larger asset base and strong alternative investment returns. The figure exceeded our estimate of $491 million and the Zacks Consensus Estimate of $513 million.
Total claims and expenses declined 17% to $3.3 billion, primarily due to lower incurred losses and loss adjustment expenses, commissions, brokerage, taxes and fees. Our estimate was $3.7 billion.
Underwriting income totaled $316 million in contrast to an underwriting loss of $104 million in the year-ago quarter.
Pre-tax catastrophe losses, net of recoveries and reinstatement premiums, were $130 million, narrower than $472 million a year ago.
The combined ratio improved 1160 basis points year over year to 91.2. The Zacks Consensus Estimate was 94.2, while our estimate was 93.9.
Q1 Segmental Update of Everest GroupReinsurance Treaty segment generated gross written premiums of $2.7 billion, down 8.5% year over year and below our estimate of $3.6 billion. The decline reflected lower volumes in Property Non-Catastrophe XOL, Casualty Pro-Rata and Casualty XOL, which were offset by growth in Property Catastrophe XOL and Financial Lines.
The segment’s combined ratio improved to 87.2 from 104.7 a year ago. Our estimate was 91.
Global Wholesale & Specialty segment posted gross written premiums of $793 million, up 1.6% year over year. Higher premiums in Accident and Health and Other Specialty were offset by declines in Property / Short Tail, Specialty Casualty, Professional Liability and Workers' Compensation.
The combined ratio improved 110 basis points year over year to 96.8. Our estimate was 100.4.
Legacy Segment posted gross written premium declined sharply by 80.3% year over year to $135 million, reflects a limited volume of renewal and new policies tied to the commercial retail insurance business. Net premiums earned fell 26.1% year over year to $399 million.
Underwriting loss widened to $22 million from $14 million incurred in the year ago quarter.
EG’s Financial UpdateEverest Group exited the first quarter of 2026 with total investments and cash of $45 billion, up 0.9% from the 2025-end level.
Shareholders’ equity fell 1.3% year over year to $15.3 billion.
Book value per share increased 1% year over year to $383.75 as of March 31, 2026.
Annualized net income return on equity improved 1110 basis points year over year to 16.8%.
Cash flow from operations totaled $649 million for the year, down 30.1% year over year.
Capital Deployment of EGEG paid common share dividends of $80 million, or $2 per share, during the reported quarter. It repurchased $331 million worth of shares in this quarter.
EG’s Zacks RankEverest Group currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance of Other InsurersChubb Limited (CB - Free Report) reported first-quarter 2026 core operating income of $6.82 per share, which outpaced the Zacks Consensus Estimate by 5.2%. The bottom line increased 85.2% year over year.
Total operating revenues improved 11.8% year over year to $15.3 billion. The top line beat the Zacks Consensus Estimate by 3%. Net premiums written improved 10.7% year over year to $14 billion in the quarter. Our estimate was $13.6 billion, while the Zacks Consensus Estimate was pegged at $13.5 billion. Net investment income was $1.7 billion, up 9.5% year over year. The Zacks Consensus Estimate was pegged at $1.8 billion, while our estimate was $2 billion.
Arch Capital Group Ltd. (ACGL - Free Report) reported first-quarter 2026 operating income of $2.50 per share, which beat the Zacks Consensus Estimate by 2.4%. The bottom line increased 15.4% year over year.
Operating revenues of $4.3 billion decreased 3.8% year over year, due to lower net premiums earned. Revenues missed the Zacks Consensus Estimate by 6.1%. Net premiums earned declined 4.8% year over year to $3.9 billion, due to lower premiums earned in its Reinsurance segment. The figure missed the Zacks Consensus Estimate by 6%.
Selective Insurance Group (SIGI - Free Report) reported first-quarter 2026 operating income of $1.69 per share, which missed the Zacks Consensus Estimate by 2.3%. The bottom line decreased 11% year over year.
Operating revenues of $1.4 billion increased 6.4% from the year-ago quarter’s level, driven primarily by higher net premiums earned and net investment income. However, the top line missed the Zacks Consensus Estimate by 0.5%. Net premiums written decreased 1% to $1.3 billion. The figure was on par with our estimate.
On April 30, 2026, Everest Group Ltd EG shares rose 3.7% today, reaching a current price of $356.76. This price is within a 52-week range of $302.44 to $368.29, highlighting the stock's recent upward momentum.
GF Value™ verdict: Current price is $356.76, which is 14.1% below the GF Value™ of $415.18.GF Score™ is 76/100, indicating an above-average rating based on several key financial metrics.Most notable signal: No insider transactions have been reported in the last three months. Is EG Overvalued or Undervalued? The current price of Everest Group Ltd EG is $356.76, which is 14.1% below the GF Value™ estimate of $415.18. This suggests that the stock is undervalued, presenting a potential opportunity for investors looking for stocks trading below their intrinsic value. The GF Valuation label indicates that EG is currently considered "Modestly Undervalued." This margin of safety could provide a buffer against market volatility, allowing investors to capitalize on a favorable pricing scenario.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Being undervalued does not guarantee future performance, and investors should consider the broader market conditions and company fundamentals before making any decisions.
How Does EG's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 7.3x 10.7x Forward P/E 6.8x - The current price-to-earnings (P/E) ratio for Everest Group Ltd EG is 7.3x, which is significantly below its 5-year median P/E of 10.7x, indicating that the stock is trading at a discount compared to its historical valuation. The forward P/E of 6.8x further emphasizes this undervaluation. This P/E analysis aligns with the GF Value™ verdict, reinforcing the notion that EG is currently undervalued, presenting a favorable opportunity for investors.
What Does EG's GF Score™ Tell Us? Metric Rating GF Score™ 76 Financial Strength 5/10 Profitability 7/10 Growth 6/10 Valuation 10/10 Momentum 2/10 The GF Score™ of 76/100 indicates that Everest Group Ltd EG is rated above average in terms of long-term investment potential. The strongest area is the Valuation rank at 10/10, suggesting that the stock is significantly undervalued compared to its peers. However, the Momentum rank is notably low at 2/10, indicating potential weaknesses in the stock's price performance momentum. The scores highlight that while there are solid fundamentals, caution should be exercised regarding short-term price movements.
What Are Insiders Doing with EG Stock? In the last three months, there have been no reported insider transactions for Everest Group Ltd EG . This lack of insider activity may suggest that executives and board members are not currently buying or selling shares, which can indicate a neutral outlook on the company's near-term prospects. In environments where insiders are active, their transactions can provide valuable insights into their confidence in the company's future performance.
What This Means for Investors Based on the GF Value™ estimate, Everest Group Ltd EG is currently undervalued, presenting a potential opportunity for investors looking for stocks priced below their intrinsic value. However, as with any investment, it is important to consider a comprehensive analysis of the company's fundamentals and market conditions before making any decisions.
For the complete analysis, visit the Everest Group Ltd EG stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is EG's GF Score™?
EG's GF Score™ is 76/100, indicating that the stock is rated above average based on key financial metrics which have been shown to correlate with higher long-term returns.
Is EG overvalued or undervalued?
EG is considered undervalued, with a GF Value™ of $415.18 compared to the current price of $356.76, suggesting a potential investment opportunity.
What is EG's P/E ratio?
The current P/E (TTM) ratio for EG is 7.3x, which is significantly below its 5-year median P/E of 10.7x, indicating that the stock is currently trading at a discount compared to its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Everest Group is executing a turnaround, refocusing on reinsurance and divesting underperforming insurance lines, with Q1 results validating early progress. Q1 earnings of $16.08 beat estimates, with a 91.2% combined ratio and $33 million in favorable reserve development, signaling improved underwriting discipline. EG's capital return is accelerating: the buyback floor increased to $300 million quarterly, and share count is down 6.3% year-over-year.
HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. (“Everest” or “the Company”) (NYSE: EG), a global underwriting leader providing world-class reinsurance and specialty insurance solutions, today announced the appointment of Lisa Davis as Head of North America, Wholesale & Specialty.
Ms. Davis will lead Everest’s North America Wholesale & Specialty business, overseeing underwriting strategy, distribution, and portfolio management across the region. She will report to Jason Keen, EVP and CEO of Global Wholesale & Specialty, and serve as a key member of his leadership team.
“Along with her extensive experience, Lisa brings a combination of underwriting discipline, operational leadership, and strong relationships that are critical in this environment,” said Jason Keen. “Her ability to build profitable specialty businesses, lead high-performing teams, and deepen broker relationships will be instrumental as we continue to strengthen our North America platform, deliver disciplined, profitable growth, and execute our long-term strategy.”
Ms. Davis brings more than 35 years of experience building and scaling specialty insurance businesses across wholesale markets, with deep expertise in underwriting leadership, portfolio management, and distribution strategy. Most recently, she led the build-out and expansion of Canopius’ U.S. business, delivering sustained profitable growth while significantly scaling the platform. Prior to that, she served as President and Chief Operating Officer for North America at Sompo America and held leadership roles at Zurich North America and St. Paul Companies.
About Everest
Everest Group, Ltd. (Everest) is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers’ most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide.
Everest common stock (NYSE: EG) is a component of the S&P 500 index.
Additional information about Everest, our people, and our products can be found on our website at www.everestglobal.com.
SAN JOSE, Calif.--(BUSINESS WIRE)--Infrrd, a global leader in Intelligent Document Processing (IDP), marks its 10th anniversary. Founded in 2016 to tackle the challenges of unstructured data, Infrrd is helping enterprises automate complex, document-heavy workflows with AI.
Headquartered in San Jose, Infrrd is a global leader in IDP, helping enterprises automate data extraction and decision-making from complex documents using AI
Share Infrrd’s platform is powered by a combined AI technology — natural language processing (NLP), machine learning (ML), and computer vision. This foundation enables organizations to extract and interpret data across structured documents like invoices and tax forms, as well as unstructured mortgage files and engineering diagrams.
Underpinning the platform is a proprietary AI engine backed by 12+ awarded patents covering innovations such as confidence scoring algorithms, document separation, entity relationship mapping, and template-invariant data extraction, ensuring consistent performance across structured, semi-structured, and unstructured documents.
Industry Recognition and Awards
“Infrrd has reinforced its position as a Leader in Everest Group's IDP PEAK Matrix® Assessment 2026. The company is differentiating through strong capabilities in document fraud detection, accuracy reasoning, and automated document splitting… and an embedded chatbot assistant. Infrrd continues to outpace the market, with above-average growth in both revenue and client adoption." — Vaibhav Bansal, Vice President, Everest Group. Infrrd has also been named a Leader in the Gartner® Magic Quadrant™ for IDP Solutions.
The Future
Looking ahead, Infrrd is advancing agentic automation through Ally, its Agentic AI layer built on top of its IDP platform. Trained on millions of real mortgage data points, Ally automates compliance, verification, and audit workflows through a chat-based interface — bringing human auditors in only when true judgment is needed.
About Infrrd
Headquartered in San Jose, Infrrd is a global leader in IDP, helping enterprises automate data extraction and decision-making from complex documents using AI. Its platform combines ML, NLP, and agentic AI and is backed by 12+ awarded patents to deliver high-accuracy, scalable automation across industries including mortgage, insurance, and financial services.
HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. announced that its Board of Directors declared a dividend of $2.00 per common share. This dividend will be payable on or before June 26, 2026 to all shareholders of record as of June 12, 2026.
About Everest
Everest Group, Ltd. (Everest) is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers’ most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide.
Everest common stock (NYSE: EG) is a component of the S&P 500 index.
Additional information about Everest, our people, and our products can be found on our website at www.everestglobal.com.
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a global data and AI company, announced it has been named a Leader in the Everest Group Healthcare Payer Intelligent Operations PEAK Matrix® Assessment 2026.
The Everest Group report examined the healthcare payer back office operations capabilities of 33 leading providers. This year’s assessment represents a meaningful evolution from the previous installment of the report, which was conducted in 2023.
In 2026, Everest expanded its scope to “Intelligent Operations,” reflecting the industry’s shift toward next-generation, AI-enabled capabilities. In addition to traditional healthcare payer operations, the evaluation now assesses providers on their ability to embed intelligent technologies—analytics, automation, and AI—across core payer functions through the value chain.
The report cited EXL’s analytics, predictive modeling, and solution flexibility as company-wide strengths, specifically within its CareRadius™ platform, which combines utilization management, case management and population health workflows with analytics-driven automation. This momentum is reinforced by strong double-digit growth in EXL’s health and life sciences business, driven by its data and AI-led strategy and the continued expansion of AI capabilities. By embedding AI more deeply across workflows, EXL is helping payers improve decision-making, streamline operations and deliver more coordinated efficient member outcomes.
“The shift toward AI-led operations is accelerating as payers seek to enhance quality, payment accuracy, and member outcomes, while navigating challenges of fragmented data and legacy cores,” says Vivek Kumar, practice director, Everest Group. “EXL is advancing its data and AI-led strategy through a mix of functional BPaaS, analytics, and platforms. Its focused investments in multiple high-demand areas such as care management and payment integrity have supported its positioning as a Leader in Everest Group’s Healthcare Payer Intelligent Operations PEAK Matrix Assessment 2026.”
“Amid rising medical costs, regulatory changes and increased administrative complexity, data management, analytics and AI have become vital tools for health plans to improve operational efficiency, drive real-time decision-making and ensure better outcomes,” said Vivek Jetley, president and head of insurance, healthcare and life sciences at EXL. “At EXL, we are committed to empowering payers with end-to-end, fully integrated solutions that streamline workflows, reduce manual processes, and enhance accuracy. By leveraging advanced analytics and AI-driven insights, we enable health plans to optimize claims processing, improve member engagement, and ensure compliance with evolving regulations. These capabilities are critical for health plans to remain resilient, agile, and competitive in an increasingly complex and demanding healthcare landscape.”
Everest Group’s PEAK Matrix® is a proprietary framework that measures an organization’s impact created within the market and the ability to deliver solutions successfully. Market Impact is evaluated through market adoption, portfolio mix and value delivered. Vision and capability, the measurement for successful solution delivery, is assessed by evaluating each firm’s vision and strategy, scope of offered services, innovation and investments, and delivery footprint. The report uses this framework to classify service providers into Leaders, Major Contenders and Aspirants.
To read more about the Everest Group 2026 report, click here.
For more information about EXL’s healthcare solutions, click here.
About EXL
EXL (NASDAQ: EXLS) is a global data and AI company that offers services and solutions to reinvent client business models, drive better outcomes and unlock growth with speed. EXL harnesses the power of data, AI, and deep industry knowledge to transform businesses, including the world's leading corporations in industries including insurance, healthcare, banking and capital markets, retail, communications and media, and energy and infrastructure, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have approximately 67,000 employees spanning six continents. For more information, visit www.exlservice.com.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL's operations and business environment, all of which are difficult to predict and many of which are beyond EXL’s control. Forward-looking statements include information concerning EXL’s possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. These statements are based on assumptions that we have made in light of management's experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although EXL believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect EXL’s actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors, which include our ability to maintain and grow client demand, our ability to hire and retain sufficiently trained employees, and our ability to accurately estimate and/or manage costs, rising interest rates, rising inflation and recessionary economic trends, are discussed in more detail in EXL’s filings with the Securities and Exchange Commission, including EXL’s Annual Report on Form 10-K. You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect EXL. EXL has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.
Our top-performing stocks this quarter were Samsung Electronics, Shell and Lam Research. Our worst contributors were IQVIA, American Express and Heidelberg. We exited our investments in Everest Group and PayPal during the quarter.
HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. (“Everest” or “the Company”) (NYSE: EG), a global specialty reinsurance and insurance leader, today announced a definitive agreement to sell Everest Compañía de Seguros Generales Colombia S.A. to American International Group, Inc. (NYSE: AIG).
The transaction builds on Everest’s previously announced sale of its global Commercial Retail Insurance renewal rights to AIG and the sale of its Canada Retail Insurance operations, marking another key step in the Company’s strategy to focus the portfolio on its core Global Reinsurance and Wholesale and Specialty Insurance businesses.
“This agreement reflects our continued progress in executing our strategy and positioning Everest for sustained, long-term performance,” said Jim Williamson, President and Chief Executive Officer of Everest. “It pairs a high-quality business with an owner well positioned to support its next phase of growth, while enabling us to strengthen leadership in the markets and capabilities where we have the strongest competitive advantage. The Colombia team has built a respected franchise, and we are confident it will continue to build on that momentum under AIG’s ownership.”
The transaction is expected to close in early 2027, subject to customary regulatory approvals and closing conditions. Advisors on the transaction include Guy Carpenter Capital & Advisory, a division of MMC Securities LLC, as financial advisor and Debevoise & Plimpton LLP as legal counsel to Everest.
About Everest
Everest Group, Ltd. (Everest) is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers’ most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide.
Everest common stock (NYSE: EG) is a component of the S&P 500 index.
Additional information about Everest, our people, and our products can be found on our website at www.everestglobal.com.
Forward-looking Statements
This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the U.S. federal securities laws. Forward-looking statements about the sale transaction, strategic repositioning and Commercial Retail Insurance operations exit plans reflect management’s current expectations based on assumptions we believe are reasonable but are not guarantees of performance. Actual results may differ materially from those contained in forward-looking statements made by or on behalf of the Company. Forward-looking statements involve risks and uncertainties including the actual impact of the sale transaction, strategic repositioning and Commercial Retail Insurance operations exit plans and other factors described in our SEC filings, including but not limited to our latest Annual Report on Form 10-K. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
NEW YORK--(BUSINESS WIRE)--American International Group, Inc. (NYSE: AIG) today announced it has entered into a definitive agreement to acquire Everest Compañía de Seguros Generales Colombia S.A. (“Everest Colombia”), Everest Group Ltd.’s (NYSE: EG) insurance subsidiary in Colombia. The acquisition of Everest Colombia strengthens AIG’s presence in the Latin America region and supports the company’s strategy to drive premium growth.
“This acquisition reinforces AIG’s commitment to our Latin America business and will enable us to accelerate our growth in one of the largest and fastest-growing insurance markets in the region,” said Jon Hancock, Executive Vice President and Chief Executive Officer, General Insurance, AIG. “With this acquisition, we are gaining a highly experienced team whose talent and deep understanding of the local market will strengthen our capabilities. Everest Colombia’s focus on corporate and upper-middle-market clients aligns with AIG’s commitment to expand our commercial insurance offerings to clients and brokers across the Latin America region.”
Upon completion of the transaction, subsidiaries of AIG will acquire 100 percent of the equity of Everest Colombia, including its licensed operations, employees and ongoing insurance business. AIG and Everest will work closely to ensure a seamless transition for clients, brokers and colleagues.
The transaction is expected to close in early 2027, subject to regulatory approvals and other customary closing conditions.
Evercore acted as financial advisor and Willkie Farr & Gallagher LLP and Brigard & Urrutia Abogados acted as legal counsel for AIG.
About AIG
American International Group, Inc. (NYSE: AIG) is a leading global insurance organization. AIG provides insurance solutions that help businesses and individuals in more than 200 countries and jurisdictions protect their assets and manage risks through AIG operations, licenses and authorizations as well as network partners. For additional information, visit www.aig.com. This website with additional information about AIG has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.
AIG is the marketing name for the worldwide operations of American International Group, Inc. All products and services are written or provided by subsidiaries or affiliates of American International Group, Inc. Products or services may not be available in all countries and jurisdictions, and coverage is subject to underwriting requirements and actual policy language. Non-insurance products and services may be provided by independent third parties. Certain property casualty coverages may be provided by a surplus lines insurer. Surplus lines insurers do not generally participate in state guaranty funds, and insureds are therefore not protected by such funds.
Key Takeaways AIG agreed to buy Everest Colombia, gaining licensed operations, employees and insurance business.The deal expands AIG's reach in Colombia and supports commercial insurance growth in Latin America.Everest is streamlining operations to focus on Global Reinsurance and Specialty Insurance businesses. American International Group, Inc. (AIG - Free Report) recently agreed to acquire Everest Group, Ltd.’s (EG - Free Report) insurance subsidiary in Colombia, a move that is expected to strengthen AIG’s footprint in Latin America and support long-term premium growth.
The transaction includes 100% of Everest Colombia’s equity, including its licensed operations, employees and ongoing insurance business. The acquisition gives AIG greater exposure to one of Latin America’s largest and fastest-growing insurance markets while expanding its commercial insurance capabilities in the region.
Everest Colombia primarily serves corporate and upper-middle-market clients, aligning well with AIG’s broader strategy to grow its commercial insurance operations across Latin America. The deal is also expected to enhance AIG’s local distribution network and deepen relationships with brokers and clients in Colombia. The transaction is expected to be closed in early 2027. Financial terms were not disclosed.
The divestiture marks another step in Everest’s ongoing strategy to streamline operations and sharpen focus on its core Global Reinsurance and Wholesale and Specialty Insurance businesses. The transaction follows Everest’s previously announced sale of its global Commercial Retail Insurance renewal rights to AIG, as well as the sale of its Canada Retail Insurance operations.
The acquisition is expected to support AIG’s efforts to expand its General Insurance business in key international markets. By adding an established local platform, experienced employees and an existing client base, AIG is positioned to accelerate growth in the Latin American market. In the first quarter of 2026, its General Insurance – International Commercial unit’s net premiums written increased 21% year over year to $2.5 billion. Also, its underwriting income increased 16% year over year to $278 million.
AIG’s Stock Price PerformanceShares of AIG have gained 2.1% over the past six months compared with the industry’s of 2.8% growth.
Image Source: Zacks Investment Research
AIG’s Zacks Rank & Key PicksAIG currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Finance space are Hamilton Insurance Group, Ltd. (HG - Free Report) , and First American Financial Corporation (FAF - Free Report) , both sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Hamilton Insurance’s 2026 earnings is pegged at $2.87 per share, which moved up 49 cents over the past 30 days. HG beat earnings estimates in each of the trailing four quarters, with the average surprise being 84.8%. The consensus estimate for 2026 revenues is pinned at $2.87 billion.
The Zacks Consensus Estimate for First American’s 2026 earnings is pegged at $6.83 per share, indicating 12.9% year-over-year growth. FAF beat earnings estimates in each of the trailing four quarters, with the average surprise being 22%. The consensus estimate for 2026 revenues is pinned at $8.05 billion, implying 8% year-over-year growth.
HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. (NYSE: RE) (“Everest”), a global underwriting leader, today announced the inaugural recipient of the Joseph V. Taranto Scholarship, an annual renewable award and part of the company’s broader commitment to expanding opportunity and developing the next generation of leaders.
Established by Everest and its Board of Directors in honor of former Chairman Joseph V. Taranto, the scholarship supports a college‑bound student who demonstrates academic excellence, financial need, and the qualities that have long defined both Everest and Mr. Taranto’s leadership: integrity, discipline, intellectual curiosity, and a commitment to service.
“Developing people and creating opportunity are fundamental to how we operate at Everest,” said Jim Williamson, Everest President and Chief Executive Officer. “This scholarship reflects our long-term commitment to investing in talent, both within our organization and in the communities we serve. It is one of many ways we’re helping build the next generation of leaders.”
The recipient was selected through a competitive process that assessed academic achievement, character, ambition, and alignment with Everest’s values.
The scholarship is part of Everest’s wider approach to “underwriting opportunity” through a combination of educational initiatives, community partnerships, and ongoing talent development programs designed to expand access and cultivate future industry leaders.
“I am deeply honored to have this scholarship carry my name,” said Joseph V. Taranto, former Chairman of Everest. “Throughout my career, I’ve believed that creating opportunities for others is the most meaningful legacy any leader can leave. Supporting young people with drive and ability is an investment that pays dividends in a broad and far-reaching way.”
The Joseph V. Taranto Scholarship complements Everest’s broader philanthropic and talent initiatives, including global giving programs, employee volunteerism, and internal development efforts that support continuous learning and career growth across the organization.
Through these efforts, Everest continues to advance its mission to “underwrite opportunity” for colleagues, customers, shareholders, and communities worldwide.
About Everest
Everest Group, Ltd. (Everest) is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers’ most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide.
Everest common stock (NYSE: EG) is a component of the S&P 500 index.
Additional information about Everest, our people, and our products can be found on our website at www.everestglobal.com.
Everest Group, Ltd. (NYSE: RE) (“Everest”), a global underwriting leader, today announced the inaugural recipient of the Joseph V. Taranto Scholarship, an annual renewable award and part of the company’s broader commitment to expanding opportunity and developing the next generation of leaders.
Established by Everest and its Board of Directors in honor of former Chairman Joseph V. Taranto, the scholarship supports a college‑bound student who demonstrates academic excellence, financial need, and the qualities that have long defined both Everest and Mr. Taranto’s leadership: integrity, discipline, intellectual curiosity, and a commitment to service.
“Developing people and creating opportunity are fundamental to how we operate at Everest,” said Jim Williamson, Everest President and Chief Executive Officer. “This scholarship reflects our long-term commitment to investing in talent, both within our organization and in the communities we serve. It is one of many ways we’re helping build the next generation of leaders.”
The recipient was selected through a competitive process that assessed academic achievement, character, ambition, and alignment with Everest’s values.
The scholarship is part of Everest’s wider approach to “underwriting opportunity” through a combination of educational initiatives, community partnerships, and ongoing talent development programs designed to expand access and cultivate future industry leaders.
“I am deeply honored to have this scholarship carry my name,” said Joseph V. Taranto, former Chairman of Everest. “Throughout my career, I’ve believed that creating opportunities for others is the most meaningful legacy any leader can leave. Supporting young people with drive and ability is an investment that pays dividends in a broad and far-reaching way.”
The Joseph V. Taranto Scholarship complements Everest’s broader philanthropic and talent initiatives, including global giving programs, employee volunteerism, and internal development efforts that support continuous learning and career growth across the organization.
Through these efforts, Everest continues to advance its mission to “underwrite opportunity” for colleagues, customers, shareholders, and communities worldwide.
About Everest
Everest Group, Ltd. (Everest) is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers’ most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide.
Everest common stock (NYSE: EG) is a component of the S&P 500 index.
Additional information about Everest, our people, and our products can be found on our website at www.everestglobal.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260521447386/en/
ORLANDO, Fla.--(BUSINESS WIRE)--Everest Group has recognized Simform as an Aspirant in the Software Product Engineering Services PEAK Matrix® Assessment 2026 - Global and EMEA.
"Everest Group's recognition reinforces our investment in scalable engineering - our PexAI framework helps organizations harness AI across the SDLC, driving faster innovation and long-term value." - Prayaag Kasundra, CEO of Simform
Share The recognition highlights Simform’s capabilities in helping organizations design, build, and scale modern digital products through product engineering expertise, cloud platforms, AI-driven engineering practices, and reusable accelerators.
As enterprises modernize digital platforms and embed AI across products and development workflows, they are seeking partners that accelerate innovation while maintaining quality, governance, and cost discipline. Simform’s inclusion reflects its role as a strategic engineering partner for enterprises, digital-native businesses, and ISVs building scalable products and platforms.
Changing Expectations for Software Product Engineering Partners
Software product engineering is entering a new phase as AI becomes embedded across both products and the software development lifecycle (SDLC).
Organizations are modernizing legacy platforms, adopting microservices architectures, and applying AI-assisted development practices to accelerate releases and improve code quality.
These shifts are driving demand for partners that combine product engineering depth, reusable accelerators, scalable delivery models, and commercial accountability.
Simform’s inclusion in Everest Group’s Software Product Engineering Services PEAK Matrix® reflects the company’s growing momentum in helping organizations modernize platforms, strengthen engineering productivity, and integrate AI-enabled capabilities across complex software ecosystems.
AI-Powered Engineering Practices Across the SDLC
To support this shift, Simform has developed an AI-native product engineering model combining cross-functional engineering pods, reusable accelerators, and AI-assisted development practices.
At the center of this model is PexAI, Simform’s flagship product engineering excellence framework. PexAI combines reusable blueprints, engineering objective frameworks, and modernization accelerators that help teams standardize architecture, streamline workflows, and scale delivery.
The framework supports modernization initiatives such as microservices architecture, cloud re-platforming, and UI transformation while enabling platform engineering through modular architectures, API-first design, AI/ML capabilities, Agentic AI-features, and data integration.
Simform applies AI across the SDLC through PexAI-driven workflows that automate tech-stack specific task/workflow based code generation, pull request reviews, infrastructure-as-code pipelines, and shift-left testing and security. This enables AI-native engineers to combine human expertise with governed AI-assisted workflows that improve productivity while maintaining reliability and compliance.
Supporting this model are proprietary accelerators such as NeuVantage, which helps teams analyze and modernize legacy applications faster, CodeTools, which enables GitHub Copilot templates, workflow agents, and automation patterns, and ThoughtMesh, which supports enterprise-grade Agentic AI use cases, including corrective RAG and agentic architectures.
Together, these frameworks help teams reduce routine development work, improve code quality, and focus on product strategy and architecture.
Moving from Capacity-Based Engineering to Outcome-Led Delivery
As software platforms become central to enterprise growth, organizations increasingly expect partners to align delivery with measurable outcomes rather than purely capacity-based engagement models.
Simform’s co-engineering approach supports this shift by embedding engineering teams within client product organizations and aligning delivery around platform modernization milestones, engineering productivity improvements, and product innovation goals. Simform is also evolving toward outcome-based commercial models where pricing is increasingly aligned with clearly defined roadmap milestones and product outcomes. For example, modernization engagements may be tied to measurable platform improvements such as successful microservices migration, release cycle acceleration, or performance gains, while product engineering programs may link commercial models to feature delivery velocity, platform stability, or engineering productivity improvements. This approach helps clients align engineering investment with tangible progress while maintaining transparency and accountability across long-running product initiatives.
“We believe software product engineering should ultimately be measured by outcomes in some ways and how effectively teams can modernize platforms, accelerate innovation, and deliver lasting business value,” said Prayaag Kasundra, CEO of Simform.
“Our PexAI framework and co-engineering delivery model help organizations harness AI across the software development lifecycle while aligning engineering execution with meaningful product and business outcomes. This recognition from Everest Group reinforces the investments we have made in building scalable engineering capabilities that enable faster innovation and long-term value for our clients.”
Transforming and Scaling Platforms with Intelligent Automation
The role of AI in platform engineering is undergoing a fundamental shift - moving from isolated automation scripts to intelligent, agentic workflows that reshape how software products are designed, built, and scaled. It is transforming the end-to-end software delivery lifecycle - from predictive resource optimization and automated security remediation to self-healing observability and CI/CD pipelines. Companies that can operationalize these capabilities at scale are pulling ahead.
"Our PexAI Framework and AI-native practices help ISVs, Digital Native, and forward-looking enterprises to modernize platforms, ship faster, improve software quality, and reduce technical debt. We have come up with Enablement offerings to enable platform and development teams with AI-native practices too," said Hiren Dhaduk, CTO of Simform.
Building AI-Native GCC and CoE
Having built excellent AI-Native engineering practices, Simform is helping software engineering teams of ISVs and enterprises adopt these advanced and mature Agentic SDLC practices to accelerate roadmaps. Simform is also partnering with customers to launch AI-Native GCC in India to double down on the value realization of engineering investments.
In addition to enabling these teams with AI-native practices, Simform helps define the operating model, governance approach, and engineering workflows needed to make GCCs and CoEs productive from the start. By combining co-engineering expertise with frameworks such as PexAI and AI-assisted SDLC practices, Simform helps organizations scale engineering capacity, improve software quality, and turn GCCs into long-term innovation engines rather than delivery-only units.
To learn more about what this shift in software product engineering means for enterprise customers, read the blog published alongside this announcement.
About Simform
Simform is a digital engineering company specializing in Cloud, Data, AI, and Experience Engineering. With deep expertise across Microsoft Azure, Simform helps high-growth ISVs and tech-enabled enterprises build scalable, future-ready digital products and platforms through its co-engineering delivery model. With a rich heritage in Microsoft technologies, Simform is recognized as a Solution Partner for Digital and App Innovation, Data & AI, Infrastructure and Security. Our team boasts 340+ Azure-certified infrastructure, cloud-native applications, data, AI and security engineers. With more than 15 years of experience, Simform delivers solutions for high-tech, fintech, healthcare & life sciences, supply chain & logistics, retail & ecommerce, and professional services industries.
It has been about a month since the last earnings report for Everest Group (EG - Free Report) . Shares have lost about 6.6% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Everest Group due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Everest Q1 Earnings Top, Revenues Miss Estimates, Premiums Decline Y/Y
Everest Group, Ltd. reported first-quarter 2026 operating income of $16.08 per share, which beat the Zacks Consensus Estimate by 14.6%. The bottom line increased significantly 149% year over year. Everest Group benefited from solid investment income growth and improved catastrophe losses, which driving a sharp improvement in profitability despite weaker premiums and top-line pressure.
EG’s Q1 Operational UpdateTotal operating revenues of about $4 billion declined 4.6% year over year, reflecting lower premiums. The top line missed the Zacks Consensus Estimate by 7.7%. Gross written premiums fell 18.5% year over year to $3.6 billion, reflecting an 8.5% decline in Reinsurance Treaty, partially offset by growth in Global Wholesale &Specialty. Our estimate was $4.8 billion.
Net investment income rose 15.5% year over year to $567 million, driven by a larger asset base and strong alternative investment returns. The figure exceeded our estimate of $491 million and the Zacks Consensus Estimate of $513 million.
Total claims and expenses declined 17% to $3.3 billion, primarily due to lower incurred losses and loss adjustment expenses, commissions, brokerage, taxes and fees. Our estimate was $3.7 billion. Underwriting income totaled $316 million in contrast to an underwriting loss of $104 million in the year-ago quarter. Pre-tax catastrophe losses, net of recoveries and reinstatement premiums, were $130 million, narrower than $472 million a year ago. The combined ratio improved 1160 basis points year over year to 91.2. The Zacks Consensus Estimate was 94.2, while our estimate was 93.9.
Q1 Segmental Update of Everest GroupReinsurance Treaty segment generated gross written premiums of $2.7 billion, down 8.5% year over year and below our estimate of $3.6 billion. The decline reflected lower volumes in Property Non-Catastrophe XOL, Casualty Pro-Rata and Casualty XOL, which were offset by growth in Property Catastrophe XOL and Financial Lines. The segment’s combined ratio improved to 87.2 from 104.7 a year ago. Our estimate was 91.
Global Wholesale & Specialty segment posted gross written premiums of $793 million, up 1.6% year over year. Higher premiums in Accident and Health and Other Specialty were offset by declines in Property / Short Tail, Specialty Casualty, Professional Liability and Workers' Compensation. The combined ratio improved 110 basis points year over year to 96.8. Our estimate was 100.4.
Legacy Segment posted gross written premium declined sharply by 80.3% year over year to $135 million, reflects a limited volume of renewal and new policies tied to the commercial retail insurance business. Net premiums earned fell 26.1% year over year to $399 million. Underwriting loss widened to $22 million from $14 million incurred in the year ago quarter.
EG’s Financial UpdateEverest Group exited the first quarter of 2026 with total investments and cash of $45 billion, up 0.9% from the 2025-end level. Shareholders’ equity fell 1.3% year over year to $15.3 billion. Book value per share increased 1% year over year to $383.75 as of March 31, 2026.
Annualized net income return on equity improved 1110 basis points year over year to 16.8%. Cash flow from operations totaled $649 million for the year, down 30.1% year over year.
Capital Deployment of EGEG paid common share dividends of $80 million, or $2 per share, during the reported quarter. It repurchased $331 million worth of shares in this quarter.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review.
VGM ScoresCurrently, Everest Group has a subpar Growth Score of D, a grade with the same score on the momentum front. However, the stock was allocated a grade of A on the value side, putting it in the top 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Everest Group has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry PlayerEverest Group is part of the Zacks Insurance - Multi line industry. Over the past month, Markel Group (MKL - Free Report) , a stock from the same industry, has gained 4.2%. The company reported its results for the quarter ended March 2026 more than a month ago.
Markel Group reported revenues of $3.55 billion in the last reported quarter, representing a year-over-year change of +0.1%. EPS of $21.61 for the same period compares with $25.72 a year ago.
For the current quarter, Markel Group is expected to post earnings of $30.20 per share, indicating a change of +18.6% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.3% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Markel Group. Also, the stock has a VGM Score of D.
Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases
Civorebrutinib adds pipeline-in-a-product potential across multiple rare kidney diseases, expanding and diversifying Travere’s pipeline
Company to host conference call June 2, 2026 at 8:30 a.m. ET
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia.
Civorebrutinib represents a strategic and complementary addition to our rare kidney disease portfolio, with the potential to become a best-in-class therapy across multiple immune-mediated rare kidney diseases.
Share “Civorebrutinib represents a strategic and complementary addition to our rare kidney disease portfolio, with the potential to become a best-in-class therapy across multiple immune-mediated rare kidney diseases,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “Patients living with rare kidney diseases still face significant unmet need, and we believe the progress made to date in IgAN and FSGS is only the beginning of what is possible for these communities. Travere has helped to deliver important firsts in these diseases, and we believe our expertise, infrastructure and deep commitment to the rare kidney community position us well to continue advancing innovation for patients. With proof-of-concept data in primary membranous nephropathy, a differentiated profile as an oral, reversible BTK inhibitor, and expected broad mechanistic applicability across diseases such as immune-mediated FSGS, minimal change disease and beyond, we believe civorebrutinib has the potential to meaningfully advance the treatment paradigm for rare kidney disease patients.”
“This collaboration with Travere brings together deep expertise in kidney disease development and commercialization and we look forward to advancing civorebrutinib in primary membranous nephropathy, immune-mediated FSGS, and minimal change disease, delivering transformative therapies for patients with serious kidney diseases worldwide,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “As a differentiated, potential best-in-class therapy, civorebrutinib has demonstrated encouraging efficacy in primary membranous nephropathy. With its highly selective and reversible covalent mechanism of action, it is well positioned to advance in development across multiple immune-mediated kidney indications. Everest remains committed to our dual-engine strategy of business development partnerships and in-house R&D. This collaboration will accelerate the global development and potential commercialization of civorebrutinib, expanding its clinical and future commercial value in autoimmune kidney diseases and the ability to deliver more innovative treatment options to patients.”
Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience for patients with rare, immune-mediated kidney diseases, including primary membranous nephropathy (PMN), with planned evaluation in focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and potentially additional indications. BTK is a key mediator of B-cell receptor signaling and plays an important role in B-cell activation, maturation, proliferation, and differentiation into antibody-producing cells.
In immune-mediated kidney diseases, B-cell activation and autoantibody production are believed to contribute directly to kidney injury. Civorebrutinib has demonstrated proof of concept in a Phase 1/2 clinical trial of patients with PMN. The previously reported Phase 1/2 data demonstrated rapid and sustained reductions in anti-PLA2R autoantibodies and proteinuria, with high rates of immunologic and clinical remission and stable kidney function through 52 weeks of follow-up. Civorebrutinib has been generally well tolerated throughout the development program to date.
As innovation in rare kidney diseases continues to accelerate, patients still face significant unmet need and limited treatment options across many serious conditions. Civorebrutinib has the potential to serve as a pipeline-in-a-product across multiple immune-mediated kidney diseases. Travere plans to investigate civorebrutinib in PMN, immune-mediated FSGS and MCD, with the potential for additional indications. These diseases share immune-mediated mechanisms that can lead to glomerular damage, resulting in proteinuria and impaired kidney function that may ultimately require dialysis or transplant. Civorebrutinib may also broaden future treatment approaches in FSGS, where both nephroprotective and targeted immune control approaches may play important roles.
Under the terms of the agreement, Everest will receive an upfront payment of $112.5 million in exchange for granting Travere exclusive development and commercialization rights for civorebrutinib in all markets outside of China and certain countries in East and Southeast Asia. Everest is also eligible to receive up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. The license agreement will become effective upon satisfaction of customary conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
Conference Call Information
Travere Therapeutics will host a conference call and webcast today, Tuesday, June 2, 2026, at 8:30 a.m. ET. To participate in the conference call, dial +1 (833) 461-5787 (U.S.) or +1 (585) 542-9983 (International), conference ID 574 733 925 shortly before 8:30 a.m. ET. The webcast can be accessed on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website.
About Civorebrutinib
Civorebrutinib (also known as EVER001) is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential component of the B-cell receptor signaling pathways that regulate the survival, activation, proliferation, and differentiation of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell autoimmune diseases.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.
The Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.
Forward Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words “on-track,” “positioned,” “look forward to,” “will,” “would,” “may,” “might,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: statements regarding the Company's beliefs about the future potential of its pipeline and portfolio; statements regarding the Company's capabilities, competitive positioning, and strategic plans; statements and expectations regarding the potential of civorebrutinib to serve as a pipeline-in-a-product and to potentially become a best-in-class therapy across multiple immune-mediated kidney diseases, and its potential to provide differentiated efficacy, safety and convenience for the indications described herein; statements and expectations regarding the expected broad mechanistic applicability across diseases; statements and expectations regarding future treatment approaches and paradigms; statements and expectations regarding the clinical studies and data described herein; statements and expectations regarding potential future payments (including upfront, milestone and royalty payments) and, as applicable, the potential achievement and timing thereof; statements and expectations regarding the activities of the Company’s partners and collaborators; and statements related to the estimated sizes of patient populations. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties related to the license agreement with Everest, including the ability of the parties to obtain required regulatory approvals and satisfy other applicable conditions, and the ability of the Company to successfully advance the product through clinical trials toward potential future regulatory approval. The Company also faces risks and uncertainties related to its business and finances in general, the success of its commercial products, risks and uncertainties associated with its preclinical and clinical stage pipeline, risks and uncertainties associated with the regulatory review and approval process, risks and uncertainties associated with enrollment of clinical trials for rare diseases, and risks that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory or other reasons. Specifically, the Company faces risks associated with the commercial launch of FILSPARI in FSGS and the ongoing commercialization in IgAN, the timing and potential outcome of its and its partners’ clinical studies, market acceptance of its commercial products including efficacy, safety, price, reimbursement, and benefit over competing therapies, risks related to the challenges of manufacturing scale-up, risks associated with the successful development and execution of commercial strategies for such products, including FILSPARI, and risks and uncertainties related to the current administration, including but not limited to risks and uncertainties related to tariffs and the funding, staffing and prioritization of resources at government agencies including the FDA. The Company also faces the risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates, including as a result of macroeconomic conditions; risks relating to the Company’s dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; and risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the Company’s products, including potential ANDA filings or patent challenges, and technological changes that may limit demand for the Company’s products. The Company also faces additional risks associated with global and macroeconomic conditions, including health epidemics and pandemics, including risks related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties, including under the heading “Risk Factors”, as included in the Company’s most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission.
Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held biotech Everest Medicines to develop and commercialize an experimental kidney disease drug in a deal worth up to $1.14 billion.
Everest Group benefits from underwriting discipline, rising investment income and global expansion while returning significant capital to shareholders.
